NTRK1 and neoplasm: In conclusion, our results indicate that oral administration of sunitinib, an inhibitor of receptor tyrosine kinases that include VEGFR, PDGFR, KIT, and CSF1R, significantly inhibits tumor growth and tumor angiogenesis in basal-like TNBC (MDA-MB-468) or claudin-low TNBC (MDA-MB-231) xenografts that highly express VEGF.